ASND compared with CYTK: revenue, margins and what each company keeps, and the suppliers and customers both name

ASNDAscendis Pharma A/S

Mkt capRevenueRevenue

CYTKCytokinetics Inc

Mkt capRevenueRevenue

Compare

ASNDAscendis Pharma A/S

CYTKCytokinetics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ASND

No earnings history for ASND.

CYTK

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.4%▼−12.66%×1.51

Q2 FY26±7.7%▼−5.67%×0.74

Q1 FY26±10.5%▼−2.92%×0.28

Feb 25 '26±10.0%▼−10.29%×1.03

= impliedASND realized, solidCYTK realized, hatchedOne scale, both sides: full bar = 13%× = |realized| ÷ impliedSource: market data

ASNDAscendis Pharma A/S

256.94▲+1.38%· post 256.91

Mkt cap$15.9BRevenue—Revenue—

CYTKCytokinetics Inc

53.83▼−3.09%· post 54.39

ClosedNov 6 '26

Mkt cap$7.5BRevenue$48MQ3 FY26Revenue$88MFY25

Compare

ClosedNov 6 '26

ASNDAscendis Pharma A/S

CYTKCytokinetics Inc

256.94▲+1.38%post 256.91

Price

53.83▼−3.09%post 54.39

$15.9B

Mkt cap

$7.5B

—

Revenue

$48MQ3 FY26

—

Revenue

$88MFY25

ASND256.94▲+1.38%vsCYTK53.83▼−3.09%ClosedNov 6 '26